🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

57 results for “Central” Clear

  1. Neoadjuvant Chemotherapy

    Xiangya Hospital of Central South University

    High-Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  2. Orelabrutinib

    The First People's Hospital of Lianyungang

    Primary Central Nervous System Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  3. PAXALISIB

    KAZIA THERAPEUTICS LTD

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  4. Pemetrexe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  5. Rozlytrek, Rozlytrek, Rozlytrek

    Hoffmann-La Roche

    Pediatric Solid tumors and primary central nervous system (CNS) tumors

    phase 2 small molecule active

    1 trial

  6. SELPERCATINIB, Selpercatinib, Selpercatinib, SELPERCATINIB, Selpercatinib

    Wuhan Createrna Science and Technology Co., Ltd

    Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  7. TEMOZOLOMIDE, TEMOZOLOMIDE, TOCILIZUMAB, CALCIUM FOLINATE, CYCLOPHOSPHAMIDE, RITUXIMAB, Lisocabtagene maraleucel, TEMOZOLOMIDE, PROCARBAZINE, FLUDARABINE, METHOTREXATE, TEMOZOLOMIDE, CALCIUM FOLINATE

    Bristol-Myers Squibb Australia Pty Ltd

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  8. Target-controlled naloxone-infusion

    BRIGHT MINDS BIOSCIENCES INC.

    Central Nervous System Sensitization

    phase 2 small molecule completed

    1 trial

  9. Valemetostat Tosylate, Golcadomide, RITUXIMAB, Valemetostat Tosylate, Golcadomide, RITUXIMAB, Golcadomide

    Celgene Europe Limited

    Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma

    phase 2 small molecule active

    1 trial

  10. [90Y]Y-PentixaTher, LysaKare 25 g/25 g solution for infusion, [68Ga]Ga-PentixaFor

    Alphapharm Pty Ltd

    Central nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondary

    phase 2 small molecule active

    1 trial

  11. interleukin-4 PE38KDEL cytotoxin

    NEUROCRINE BIOSCIENCES INC

    Brain and Central Nervous System Tumors

    phase 2 mab completed

    1 trial

  12. lymphokine-activated killer cells

    LISATA THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 2 mab terminated

    1 trial

  13. nedaplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  14. palifosfamide

    Alaunos Therapeutics

    Adult Central Nervous System Germ Cell Tumor

    phase 2 small molecule terminated

    1 trial

  15. temozolomide

    Children's Hospital of Fudan University

    Brain and Central Nervous System Tumors

    phase 2 small molecule completed

    1 trial

  16. A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Participants with BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with Central Nervous System Metastases

    Hoffmann-La Roche

    BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with or without Central Nervous System Metastases

    phase 1 other active

    1 trial

  17. GDC-0084

    KAZIA THERAPEUTICS LTD

    Brain and Central Nervous System Tumors

    phase 1 small molecule completed

    1 trial

  18. LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules, Bavencio 20 mg/mL concentrate for solution for infusion, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules

    Merck Sharp and Dohme

    Central Nervous System Tumors

    phase 1 small molecule active

    1 trial

  19. Loncastuximab tesirine and rituximab (Lonca-R)

    ADC Therapeutics SA

    Central Nervous System Lymphoma

    phase 1 small molecule active

    1 trial

  20. ONC206

    Jazz Pharmaceuticals Ireland Limited

    Central Nervous System Neoplasms

    phase 1 small molecule active

    1 trial

  21. ONC206 Powder

    AXIM BIOTECHNOLOGIES, INC.

    Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

    phase 1 small molecule active

    1 trial

  22. VEGF inhibitor PTC299

    PTC THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 1 small molecule completed

    1 trial

  23. liposomal cytarabine

    Pacira Ireland Limited

    Brain and Central Nervous System Tumors

    phase 1 small molecule active

    1 trial

  24. Aflibercept (2.0 mg)

    Regeneron UK Limited

    Macular Edema With Central Retinal Vein Occlusions

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources